Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

REVEALED: 13 | Vintage Vibes

Why Mounjaro sales to UK wholesalers have been suspended

IN FULL

The Independent UK

Mounjaro weight loss jab sales are halted in the UK as drugmaker looks to beat price rise

Eli Lilly, the manufacturer of Mounjaro, has temporarily suspended deliveries of the drug to UK pharmacies in response to ‘unprecedented demand’

Evening Standard

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sales of Mounjaro weight loss jab to UK suspended as pharmacies hit by shortage ahead of price hike

Boots and Lloyds pharmacies among those running low after users stockpile drug ahead of price hike

The Independent UK

New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate significant progress in survival outcomes for high-risk early breast cancer patients.

Benzinga

‘I lost more than 2 stone on Mounjaro - but my hair started to fall out’

Rhiannon Anne Griffiths-Bowen says the weight-loss benefits of taking Mounjaro outweighed the issue of hair loss

The Independent UK

Eli Lilly Stock Jumps On Weight-Loss Pill Trial

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

MarketBeat

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

The Independent UK

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Benzinga

Eli Lilly’s once-daily weight loss pill succeeds in latest trial, paving the way for global approval

Lilly said it plans to ask regulators to approve the drug by the end of 2025.

Euronews

‘Gutted’: UK users of weight loss jab Mounjaro devastated by planned price hike

People using the jab reported positive results, but many say the increased cost will be prohibitively expensive, and they expect to put the weight back on when they stop

The Guardian - UK

Mounjaro users in UK warned against bulk buying before autumn price rise

Cost may increase as much as 170% from September, but patients warned against a quick switch to Wegovy

The Guardian - UK

UK Sales of Wegovy Skyrocket 2,000% as Dieters Dump Mounjaro After 170% Price Hike

This trend drove WeGovy sales to jump 27 times higher — a 2,660% increase — on Wednesday compared with the typical daily average last month.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

The Saturday Spread: 3 Beaten-Down Stocks That Are Potentially Poised for a Recovery (V, LLY, ABNB)

Although the market has been uncomfortably choppy in recent sessions, this is also the time for contrarians to pick up hot securities on the cheap.

Benzinga

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Euronews

Serena Williams reveals GLP-1 treatment helped her lose 31 pounds after giving birth

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

The Independent UK

Sales of Wegovy weight loss jabs soar 27-fold after rival Mounjaro ramps up price in UK

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Wegovy sales spike after maker of rival Mounjaro ramps up UK price

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

MarketBeat

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

Benzinga

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

International Business Times UK

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

MarketBeat

Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.